Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Alnylam Pharmaceuticals, Inc. NASDAQ: ALNY. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Alnylam Pharmaceuticals stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Alnylam Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:ALNY traded up $0.81 during midday trading on Friday, reaching $328.81. The company had a trading volume of 666,672 shares, compared to its average volume of 894,987. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $333.70. The firm has a market cap of $42.87 billion, a price-to-earnings ratio of -157.33 and a beta of 0.23. The company has a fifty day simple moving average of $310.69 and a two-hundred day simple moving average of $274.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter last year, the business earned ($0.16) EPS. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Needham & Company LLC raised their price objective on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Citigroup raised their price objective on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research report on Monday, June 30th. Finally, Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $347.75.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $1,045,822,000. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Capital Research Global Investors boosted its stake in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.